Linaprazan glurate

Cinclus Pharma has partnered with Zentiva to commercialize linaprazan glurate, a next-generation potassium-competitive acid blocker (PCAB) for severe erosive GERD, in a deal valued at €220 million.

Cinclus Pharma has completed all third-party supplier contracts for its upcoming Phase III study of linaprazan glurate, positioning the next-generation PCAB for advanced clinical evaluation.

Cinclus Pharma reached an agreement with the FDA on its initial Pediatric Study Plan (iPSP) for linaprazan glurate, a crucial step for potential market approval in the US.

Cinclus Pharma has reached an agreement with the European Medicines Agency (EMA) regarding a pediatric study plan for linaprazan glurate, a drug intended for adult patients.

Cinclus Pharma has reached an agreement with the EMA on a Pediatric Investigation Plan (PIP) for linaprazan glurate, a key step for potential marketing approval in the EU.